Fate Therapeutics Inc (FATE) — 10-Q Filings

10-Q Filings (6)

• Fate Therapeutics Narrows Losses Amid Restructuring, Revenue Dip — Nov 13, 2025 Risk: high
  FATE THERAPEUTICS INC reported a net loss of $32.25 million for the three months ended September 30, 2025, a 32.4% improvement from the $47.68 million net loss
• Fate Therapeutics' Q2 Loss Widens Amid R&D Surge — Aug 12, 2025 Risk: high
  FATE THERAPEUTICS INC reported a net loss of $62.3 million for the three months ended June 30, 2025, a significant increase from the $50.1 million net loss in t
• Fate Therapeutics Q1 2025 Update — May 13, 2025 Risk: medium
  Fate Therapeutics Inc. reported its first quarter results for the period ending March 31, 2025. The company's financial statements indicate various assets and l
• Fate Therapeutics Q3 2024 Update — Nov 12, 2024 Risk: medium
  Fate Therapeutics Inc. reported its third-quarter results for the period ending September 30, 2024. The company's financial statements indicate ongoing operatio
• Fate Therapeutics Files 10-Q for Q2 2024 — Aug 13, 2024 Risk: medium
  Fate Therapeutics Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and operational highlights. Key financial
• Fate Therapeutics Files 10-Q for Period Ending March 31, 2024 — May 9, 2024 Risk: medium
  FATE THERAPEUTICS INC (FATE) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. FATE Therapeutics Inc. filed a 10-Q report for the period ending March

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX